CIK 0002058707 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Attovia Therapeutics, Inc.
Sign in to watch- Ticker
- ATTO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 921510574
- Phone
- 5103995001
- Business address
- 1091 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-06 | WALSH COLIN Director | Conversion | +1,957,134 | 2,042,134 | ||
| 2026-08-06 | WALSH COLIN Director | Conversion | +478,498 | 2,520,632 | ||
| 2026-08-06 | WALSH COLIN Director | Purchase | +500,000 | $17.00 | $8.5M | 3,020,632 |
| 2026-08-06 | WALSH COLIN Director | Conversion · Series B Preferred Stock | −18,181,830 | 0 | ||
| 2026-08-06 | WALSH COLIN Director | Conversion · Series C Preferred Stock | −4,445,275 | 0 | ||
| 2026-08-06 | GOLDMAN SACHS GROUP INC Former 10% Owner | Conversion | +1,957,134 | 2,042,134 | ||
| 2026-08-06 | GOLDMAN SACHS GROUP INC Former 10% Owner | Conversion | +478,498 | 2,520,632 | ||
| 2026-08-06 | GOLDMAN SACHS GROUP INC Former 10% Owner | Purchase | +500,000 | $17.00 | $8.5M | 3,020,632 |
| 2026-08-06 | GOLDMAN SACHS GROUP INC Former 10% Owner | Conversion · Series B Preferred Stock | −18,181,830 | 0 | ||
| 2026-08-06 | GOLDMAN SACHS GROUP INC Former 10% Owner | Conversion · Series C Preferred Stock | −4,445,275 | 0 | ||
| 2026-08-06 | WALSH COLIN Director | Conversion | +1,957,134 | 2,042,134 | ||
| 2026-08-06 | WALSH COLIN Director | Conversion | +478,498 | 2,520,632 | ||
| 2026-08-06 | WALSH COLIN Director | Purchase | +500,000 | $17.00 | $8.5M | 3,020,632 |
| 2026-08-06 | WALSH COLIN Director | Conversion · Series B Preferred Stock | −18,181,830 | 0 | ||
| 2026-08-06 | WALSH COLIN Director | Conversion · Series C Preferred Stock | −4,445,275 | 0 | ||
| 2026-08-06 | GOLDMAN SACHS GROUP INC Former 10% Owner | Conversion | +1,957,134 | 2,042,134 | ||
| 2026-08-06 | GOLDMAN SACHS GROUP INC Former 10% Owner | Conversion | +478,498 | 2,520,632 | ||
| 2026-08-06 | GOLDMAN SACHS GROUP INC Former 10% Owner | Purchase | +500,000 | $17.00 | $8.5M | 3,020,632 |
| 2026-08-06 | GOLDMAN SACHS GROUP INC Former 10% Owner | Conversion · Series B Preferred Stock | −18,181,830 | 0 | ||
| 2026-08-06 | GOLDMAN SACHS GROUP INC Former 10% Owner | Conversion · Series C Preferred Stock | −4,445,275 | 0 |
Page 1 of 9 · 162 trades